טאבניק  500 מג תמיסה לאינפוזיה תוך ורידית ישראל - עברית - Ministry of Health

טאבניק 500 מג תמיסה לאינפוזיה תוך ורידית

sanofi - aventis israel ltd - levofloxacin as hemihydrate - תמיסה לאינפוזיה - levofloxacin as hemihydrate 5 mg/ml - levofloxacin - levofloxacin - in adults for whom intravenous therapy is considered to be appropriate, tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: community- acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

טאבניק טבליות 500 מג ישראל - עברית - Ministry of Health

טאבניק טבליות 500 מג

sanofi israel ltd - levofloxacin as hemihydrate - טבליות מצופות פילם - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - in adults with infections of mild to moderate severity tavanic tablets are indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

טארגוציד 200 מג ישראל - עברית - Ministry of Health

טארגוציד 200 מג

sanofi - aventis israel ltd - teicoplanin - אבקה להכנת תמיסה לזריקה - teicoplanin 200 mg - teicoplanin - teicoplanin - for treatment of potentially serious gram-positive infections including those which cannot be treated with other antimicrobial drugs e.g.penicillins and cephalosporins.

מנקטרה ישראל - עברית - Ministry of Health

מנקטרה

sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - תמיסה להזרקה - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 mouths through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.

אימווקס DT ישראל - עברית - Ministry of Health

אימווקס dt

sanofi israel ltd - aluminium hydroxide; diphtheria toxoid; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid 2 iu / 0.5 ml; tetanus toxoid 20 iu / 0.5 ml; aluminium hydroxide 0.6 mg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - this vaccine is indicated for adults over 18 years of age in the following cases:- routine booster vaccinations against diphtheria and tetanus. the diphtheria toxoid content is reduced to one tenth of the normal dose to minimize the risks of a severe hypersensitivity reaction.- primary vaccination.- post-exposure prophylaxis following a tetanus-prone wound, if a booster diphtheria injection is required.this adsorbed diphtheria and tetanus vaccine may be administered as a booster vaccination in children over 10 years of age in whom poliomyelitis is prevented by separate administration of poliomyelitis vaccine.

טייפים וי ישראל - עברית - Ministry of Health

טייפים וי

sanofi israel ltd - purified vi capsular polysaccharide of s.typhi - תמיסה להזרקה - purified vi capsular polysaccharide of s.typhi 0.025 mg / 0.5 ml - typhoid, purified polysaccharide antigen - typhoid, purified polysaccharide antigen - typhim vi vaccine is indicated for active immunization against typhoid fever for persons two years of age or older.

אווקסים פדיאטרי 80 U ישראל - עברית - Ministry of Health

אווקסים פדיאטרי 80 u

sanofi israel ltd - hepatitis a vaccines - תרחיף להזרקה - hepatitis a vaccines 80 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - avaxim 80 u pediatric is indicated for active immunisation against infection caused by hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.

ורוראב ישראל - עברית - Ministry of Health

ורוראב

sanofi israel ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תרחיף להזרקה - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

אדסל פוליו ישראל - עברית - Ministry of Health

אדסל פוליו

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.

טקסוטר ישראל - עברית - Ministry of Health

טקסוטר

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.